Peter Lebowitz, Third Arc Bio CEO
July 23, 2024 07:00 AM EDTUpdated August 20, 10:19 AM
Financing
Startups

At Third Arc Bio, for­mer J&J lead­ers raise $165M to test on­col­o­gy, au­toim­mune bi­o­log­ics

Kyle LaHucik

Senior Reporter

Af­ter more than a decade steer­ing John­son & John­son’s on­col­o­gy drug R&D, Pe­ter Lebowitz is ready for his next chal­lenge: shep­herd­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: In­flu­en­tial De­mo­c­rat will op­pose Biose­cure Act ahead of House vote

Astel­las CEO talks fu­ture be­yond Xtan­di as Japan­ese drug­mak­er puts roots in Boston

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Roche's Spark los­es CEO to RNA up­start; Ex-El­e­va­tion On­col­o­gy chief takes over at Af­fimed

Lil­ly inks obe­si­ty deal with seed-stage RNA start­up as its ge­net­ic med­i­cines ef­fort en­ters the spot­light

sponsored

How to se­cure full en­roll­ment and a 30x ROI: A con­ver­sa­tion with the CEO of the bou­tique en­roll­ment agency do­ing just ...

A service from the Financial Times